LUGPA Annual Meeting

David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.

According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.

Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.

In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.